<DOC>
	<DOCNO>NCT00263328</DOCNO>
	<brief_summary>A new immunosuppressive drug , base inhibition important enzyme immune system call JAK3 , develop Pfizer prevent transplant rejection . In study A3921009 , kidney transplant patient give JAK inhibitor tacrolimus 6 month posttransplant . Patients complete study A3921009 offer opportunity participate study A3921021 extend evaluation safety efficacy CP-690,550 versus tacrolimus 8 year posttransplant . In treatment group 1 ( control arm ) , subject continue receive tacrolimus . In treatment group 2 3 , subject continue receive CP-690,550 . Per Amendment 4 , tacrolimus comparator arm discontinue .</brief_summary>
	<brief_title>Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Enrollment Stage 1 Study A3921009 complete 6months treatment trial medication ( CP690,550 tacrolimus ) Recipient firsttime kidney transplant Subject untreated condition may affect drug absorption ( eg , gastrectomy clinically significant diabetic gastroenteropathy ) . Subjects wait list second kidney transplant nonrenal organ transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>immunosuppression</keyword>
	<keyword>JAK3 inhibitor</keyword>
	<keyword>kidney transplant</keyword>
	<keyword>tofacitinib</keyword>
	<keyword>Xeljanz</keyword>
	<keyword>CP-690</keyword>
	<keyword>550</keyword>
	<keyword>tacromilus</keyword>
	<keyword>mycophenolate mofetil</keyword>
</DOC>